Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This editorial comment discusses previous studies on finasteride's impact on prostate cancer development and provides no new research findings.

This letter to the editor references a study on using dihydrotestosterone gel before hypospadias surgery but itself contains no new findings.

This editorial comment in the Journal of Urology discusses the implications of the Prostate Cancer Prevention Trial but reports no new research findings.

This article presents a therapeutic perspective on Proscar and Propecia for treating prostate conditions but reports no new research findings.

This article discusses a novel approach to treating recurrent priapism in sickle cell anemia using Finasteride, but provides no new clinical findings.

This article describes the unusual anti-angiogenic effects of combined hormonal blockade but reports no new research findings.

The conclusion is that future trials should report specific details about the PRP composition to better understand its effects on urologic conditions.

Eating more omega-3 and less omega-6 fatty acids may lower the risk of developing prostate cancer.

This meta-analysis reported that dietary intake of omega-3 or omega-6 fatty acids does not significantly impact prostate cancer risk.

This paper discusses the potential of PSA doubling time after radical prostatectomy to predict overall survival but reports no new results.

Low dose finasteride causes only minor changes in PSA levels in men over 50 with BPH.

This study found that some cancer cells exhibit neuronal-like characteristics, which may serve as a mechanism of resistance.

This study found that prolonged use of finasteride and dutasteride in young men with androgenic alopecia is linked to a decline in semen quality over time, particularly affecting sperm motility and DNA integrity, with dutasteride showing a slightly greater impact than finasteride.

This study found that men taking 1 mg/day of finasteride had significantly reduced sperm production and morphology but similar hormonal, sexual, and psychological profiles compared to controls, suggesting finasteride affects semen quality without altering other physiological functions.

In this large retrospective study, low-dose finasteride for androgenetic alopecia was associated with an increased risk of erectile dysfunction at one and three years among men aged 18-45.

In this study, men using finasteride-1 mg long-term for androgenic alopecia were more likely to receive PDE5i prescriptions sooner than non-users, while also having reduced rates of elevated PSA and prostate cancer diagnoses.

In this study, researchers found that methylation of the SRD5A2 gene in blood and tissue samples can serve as a biomarker to predict men's clinical response to finasteride treatment for benign prostatic hyperplasia, offering a non-invasive method for assessing potential treatment success.

This study observed that although 5-alpha-reductase inhibitors reduce PSA density in patients on active surveillance for prostate cancer, those who progress to more serious disease still show higher PSA densities, suggesting these inhibitors accentuate differences in clinically significant cases.

This study found that 5-alpha reductase inhibitors had the highest association with erectile dysfunction reports among medications analyzed in the FDA's national pharmacovigilance database.

This study found that tadalafil use was associated with a decreased risk of major adverse cardiac events and venous thromboembolism in men with lower urinary tract symptoms.

This study found that testosterone and finasteride were significantly associated with reports of male-factor infertility based on FDA pharmacovigilance data from 2010 to 2020.

This editorial discusses cardiac failure associated with medical therapy for benign prostatic hyperplasia, reporting no new original research findings.

This editorial comments on a European registry evaluating the symptomatic effectiveness of pharmacological treatments for benign prostatic enlargement and presents no new research findings.

This study found that big chain pharmacies in Pennsylvania charged significantly higher prices for generic BPH medications compared to independent pharmacies, which had more regional price variation.

This study found that bilateral orchiectomy allows most transgender women to stop anti-androgen medications, with 91.7% discontinuing them post-surgery and 25% reducing estrogen use.

This article reviews the impact of 5α-reductase inhibitors on prostate cancer detection and mortality but provides no new clinical results.

After the FDA's 2011 warning about a potential prostate cancer risk with 5-alpha reductase inhibitors, this study observed a significant decrease in their prescriptions, notably a 49% drop among men with benign prostatic hyperplasia, while primary care providers reduced prescriptions by 60%.

This study found that in 45-year-old German men, the use of metformin, insulin, and ACE inhibitors was associated with lower PSA levels, while low dose finasteride resulted in notable PSA decrease.

This study observed that urologists are more likely than primary care physicians to prescribe a variety of alpha blockers and newer medications, indicating a broader awareness of treatment options for benign prostate enlargement.